NASDAQ:ORMP Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis $2.26 -0.04 (-1.74%) (As of 11/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Oramed Pharmaceuticals Stock (NASDAQ:ORMP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oramed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.26▼$2.3050-Day Range$2.17▼$2.5152-Week Range$2.00▼$3.67Volume60,933 shsAverage Volume107,531 shsMarket Capitalization$91.10 millionP/E Ratio4.43Dividend YieldN/APrice TargetN/AConsensus RatingHold Company OverviewOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Oramed Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks30th Percentile Overall ScoreORMP MarketRank™: Oramed Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat, and ranked 787th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Oramed Pharmaceuticals.Read more about Oramed Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from $0.24 to ($0.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oramed Pharmaceuticals is 4.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Oramed Pharmaceuticals is 4.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 97.34.Price to Book Value per Share RatioOramed Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.74% of the outstanding shares of Oramed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently increased by 0.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOramed Pharmaceuticals does not currently pay a dividend.Dividend GrowthOramed Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.74% of the outstanding shares of Oramed Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverOramed Pharmaceuticals has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oramed Pharmaceuticals has recently increased by 0.50%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News SentimentN/A News SentimentOramed Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oramed Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 7 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Oramed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.Read more about Oramed Pharmaceuticals' insider trading history. Receive ORMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oramed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORMP Stock News HeadlinesOramed Pharm (ORMP) Receives a Hold from H.C. WainwrightSeptember 9, 2024 | markets.businessinsider.comORMP: Balance Sheet Strong, Potential Benefits of Investments, JVs, BuybacksAugust 30, 2024 | finance.yahoo.comJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.November 21, 2024 | Priority Gold (Ad)3 Micro-Cap Moonshots for Fearless InvestorsJuly 8, 2024 | investorplace.comOramed Letter to ShareholdersJune 26, 2024 | prnewswire.comOramed Pharmaceuticals Inc. Announces the Buy-Back of its Common StockJune 26, 2024 | prnewswire.comORMP: Moving Oral Delivery Platform Forward, + Potential to Generate RoyaltiesMay 29, 2024 | finance.yahoo.comOramed Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)May 12, 2024 | finance.yahoo.comSee More Headlines ORMP Stock Analysis - Frequently Asked Questions How have ORMP shares performed this year? Oramed Pharmaceuticals' stock was trading at $2.31 at the start of the year. Since then, ORMP stock has decreased by 2.2% and is now trading at $2.26. View the best growth stocks for 2024 here. How were Oramed Pharmaceuticals' earnings last quarter? Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings results on Monday, January, 10th. The biotechnology company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.17) by $0.06. The biotechnology company had revenue of $0.67 million for the quarter, compared to the consensus estimate of $0.70 million. Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' top institutional shareholders include BML Capital Management LLC (5.36%), Murchinson Ltd. (4.24%), Connor Clark & Lunn Investment Management Ltd. (0.27%) and XTX Topco Ltd (0.06%). Insiders that own company stock include Michael Rabinowitz, Nadav Kidron, Yadin Rozov and Kevin Rakin. View institutional ownership trends. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD). Company Calendar Last Earnings1/10/2022Today11/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORMP CUSIPN/A CIK1176309 Webwww.oramed.com Phone(844) 967-2633Fax972-2566-0004Employees10Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.51 Trailing P/E Ratio4.43 Forward P/E Ratio9.42 P/E GrowthN/ANet Income$5.53 million Net MarginsN/A Pretax Margin1,518.25% Return on Equity-7.28% Return on Assets-6.22% Debt Debt-to-Equity RatioN/A Current Ratio27.08 Quick Ratio27.08 Sales & Book Value Annual Sales$1.34 million Price / Sales67.99 Cash FlowN/A Price / Cash FlowN/A Book Value$4.04 per share Price / Book0.56Miscellaneous Outstanding Shares40,310,000Free Float34,789,000Market Cap$91.10 million OptionableOptionable Beta1.77 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ORMP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oramed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oramed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.